Valneva SE (VALN) Equity Income (2021)

Valneva SE's (VALN) quarterly Equity Income came in at $131556.7 in Q4 2021, up 471.85% quarter-over-quarter from -$35378.6 in Q3 2021.

Valneva SE (VALN) Equity Income (2021) Analysis & Trends

Valneva SE has disclosed Equity Income across 1 years of filings, most recently posting $131556.7 for Q4 2021.

Equity Income for Q4 2021 came in at $131556.7, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $131556.7 (up 1132.41% YoY), and the FY2022 annual result was $9182.2, up 255.18% from the prior year.
Equity Income came in at $131556.7 for Q4 2021 at Valneva SE, up from -$35378.6 in the prior quarter.
In the past five years, Equity Income ranged from a high of $131556.7 in Q4 2021 to a low of -$85503.3 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	235,807.00
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	-
9	Abivax	94.26 Bn	94.26 Bn	-	-
10	Valneva SE	167.33 Mn	44.10 Mn	5.08 Mn	-

Download Data